CD8+ T cell tolerance and cancer immunotherapy

被引:45
作者
de Visser, KE [1 ]
Schumacher, TNM [1 ]
Kruisbeek, AM [1 ]
机构
[1] Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands
关键词
cancer immunotherapy; CD8(+) T cell tolerance;
D O I
10.1097/00002371-200301000-00001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To provide protection against all foreign pathogens one can possibly encounter during their lifetime, the T cell repertoire has to be as diverse as possible. At the same time, it is desirable that the T cell repertoire remains unresponsive towards healthy tissues. To realize this self/nonself discriminatory property, T cells undergo tightly controlled selection processes during maturation in the thymus. The key parameter determining the outcome of these selection processes is the avidity of the T cells for self-MHC/self-peptide complexes expressed in the thymus; low avidity interactions result in positive selection, whereas high avidity interactions lead to negative selection. Despite the selection processes, self-tolerance is far from absolute. In many cases, this is due to the presence of self-antigen in the thymus at a level that is too low to induce thymic deletion. In addition, T cells with a low avidity for ubiquitously expressed self-antigens can escape clonal deletion and enter the periphery. A thorough understanding of the self-specific T cell repertoire is important because many potential targets for cancer immunotherapy are self-proteins. In this review, the authors discuss the impact of self-antigen expression on the CD8(+) T cell repertoire. An overview of the fate and functional capacities of self-specific T cells with specificity for tissue-restricted self-antigens and for ubiquitously expressed self-antigens is provided. Furthermore, the authors discuss the influence of negative selection on the antitumor reactivity of the mature T cell repertoire. Key Words: Cancer immunotherapy-CD8(+) T cell tolerance.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 134 条
[21]   Low-avidity self-specific T cells display a pronounced expansion defect that can be overcome by altered peptide ligands [J].
de Visser, KE ;
Cordaro, TA ;
Kessels, HWHG ;
Tirion, FH ;
Schumacher, TNM ;
Kruisbeek, AM .
JOURNAL OF IMMUNOLOGY, 2001, 167 (07) :3818-3828
[22]  
de Visser KE, 2000, EUR J IMMUNOL, V30, P1458, DOI 10.1002/(SICI)1521-4141(200005)30:5<1458::AID-IMMU1458>3.0.CO
[23]  
2-2
[24]   Heteroclitic immunization induces tumor immunity [J].
Dyall, R ;
Bowne, WB ;
Weber, LW ;
LeMaoult, J ;
Szabo, P ;
Moroi, Y ;
Piskun, G ;
Lewis, JJ ;
Houghton, AN ;
Nikolic-Zugic, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (09) :1553-1561
[25]   DUAL T-CELL RECEPTOR ALPHA-CHAIN T-CELLS IN AUTOIMMUNITY [J].
ELLIOTT, JI ;
ALTMANN, DM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (04) :953-959
[26]   Selecting and maintaining a diverse T-cell repertoire [J].
Goldrath, AW ;
Bevan, MJ .
NATURE, 1999, 402 (6759) :255-262
[27]  
Grohmann U, 1997, J IMMUNOL, V158, P3593
[28]   Activation of autoreactive T cells by peptides from human pathogens [J].
Hausmann, S ;
Wucherpfennig, KW .
CURRENT OPINION IN IMMUNOLOGY, 1997, 9 (06) :831-838
[29]   EXPRESSION OF 2 T-CELL RECEPTOR-ALPHA CHAINS ON THE SURFACE OF NORMAL MURINE T-CELLS [J].
HEATH, WR ;
CARBONE, FR ;
BERTOLINO, P ;
KELLY, J ;
COSE, S ;
MILLER, JFAP .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (06) :1617-1623
[30]  
Hemmer B, 1998, J IMMUNOL, V160, P5807